First clinical experiences with perampanel—The Kork experience in 74 patients. (January 2014)

• Record Type: Journal Article
• Authors: Steinhoff, Bernhard J.; Bacher, Matthias; Bast, Thomas; Kornmeier, Reinhold; Kurth, Christoph; Scholly, Julia; Staack, Anke M.; Wisniewski, Ilona
• Is Part Of: Epilepsia. Volume 55(2014)Supplement 1
• Page Start: 16
• Page End: 18
• Publication Date: 2014-01
• Subjects: Perampanel -- Clinical experience -- Efficacy -- Tolerability -- Retention rate; Epilepsy -- Periodicals; 616.853
• DOI: 10.1111/epi.12492
• Languages: English
• ISSNs: 0013-9580

Abstract

Summary: Perampanel (PER) has been approved for adjunctive treatment of partial‐onset seizures in patients age 12 years and older. In Germany, PER was licensed and marketed in September of 2012. At our tertiary referral epilepsy center, a couple of difficult‐to‐treat patients were awaiting this introduction of PER; therefore, we were able to initiate treatment in many patients within a short period of time. For this report we collected and analyzed the data of the first patients who had been started on add‐on PER between September and December of 2012, so that we were able to evaluate at least 6 months of treatment when we made this analysis. At cutoff in June of 2013, 74 patients could be analyzed. Mean age was 38.4 years (range 15–71 years). PER doses ranged from 4 to 14 mg (mean 8.8 mg). All patients took PER once daily at bedtime. Seventy‐one patients had focal epileptic seizures; the remaining four patients had Lennox‐Gastaut syndrome. Considering the last 3 months of observation compared with baseline, 34 patients (46%) were responders with a reduction of seizure frequency of at least 50%. Ten patients of these (14% of all) were seizure‐free. Adverse events were reported in 40 patients (54%). Leading side effects were somnolence (n = 31, 42%) and dizziness (n = 13, 18%), followed by ataxia, irritability, falls, cognitive slowing, and depression in single cases. Six‐month retention rate was 70%. Our first clinical experiences with add‐on PER in a highly selected group of difficult‐to‐treat epilepsies are promising.